Synthesis and Biological Activity of New Donepezil-Hydrazinonicotinamide Hybrids decreased level of choline acetyltransferase, leading to impaired synthesis and uptake of acetylcholine (ACh) neurotransmitter [ 3 , 4 ] . As ACh is degraded by cholinesterase, it stands to reason that cholinergic transmission can be improved by inhibiting the activity of this enzyme. 2 kinds of choline esterases catalyzing hydrolysis of choline esters exist in the central nervous system: acetylcholinesterase (AChE), the so-called true esterase, and butyrylcholinesterase (BChE), referred to as pseudocholinesterase or non-specifi c cholinesterase. AChE is bound to the membrane of cholinergic neurons, whereas BChE is present both in the neurons and in the glial cells. Both enzymes show 65 % homology, and the main diff erences pertain to their substrate specifi city. Acetylcholinesterase selectively and rapidly hydrolyzes acetylcholine in cholinergic synapses. In turn, butyrylcholinesterase can also hydrolyze butyrylcholine and some medications and drugs, aside from acetylcholine. Moreover, it regulates cholinergic transmission in states of acetylcholinesterase defi ciency. In healthy individuals, AChE accounts for 80 % of esterase activity within the central nervous system, whereas the remaining 20 % is provided by BChE. In Alzheimer's disease, the activity of AChE can be reduced to 67 % of normal level in certain brain regions; simultaneously, an Introduction ▼ Alzheimer's disease (AD) is a slow progressive, degenerative disorder of the CNS. It is the most common form of dementia accounting for about 50-60 % of all cases of dementia among persons over 65 years of age. Currently, an estimated 4.5 million older people suff er with Alzheimer's disease (AD), and researchers predict that by 2 050 the number could nearly triple, to 13.5 million [ 1 ] . This disease is important not only because of the number of aff ected patients but also because it leads to signifi cant physical and emotional burden on families and caregivers. Alzheimer's disease is characterized by the loss of memory and learning ability, together with a reduced ability to perform basic activities of daily living. AD patients exhibit marked neuropsychiatric symptoms such as apathy, irritability, anxiety, depression, hallucinations and verbal and physical agitation [ 2 ] . Studies performed during the last 20 years revealed that disordered cholinergic transmission is behind cognitive impairment present in Alzheimer's disease patients. The disorders in transmission result from the reduced number of cholinergic neurons in brain regions associated with higher cognitive functions, i. e. in the neocortex and hippocampus, as well as from the 
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▼
Alzheimer's disease (AD) is a slow progressive, degenerative disorder of the CNS. It is the most common form of dementia accounting for about 50-60 % of all cases of dementia among persons over 65 years of age. Currently, an estimated 4.5 million older people suff er with Alzheimer's disease (AD), and researchers predict that by 2 050 the number could nearly triple, to 13.5 million [ 1 ] . This disease is important not only because of the number of aff ected patients but also because it leads to signifi cant physical and emotional burden on families and caregivers. Alzheimer's disease is characterized by the loss of memory and learning ability, together with a reduced ability to perform basic activities of daily living. AD patients exhibit marked neuropsychiatric symptoms such as apathy, irritability, anxiety, depression, hallucinations and verbal and physical agitation [ 2 ] . Studies performed during the last 20 years revealed that disordered cholinergic transmission is behind cognitive impairment present in Alzheimer's disease patients. The disorders in transmission result from the reduced number of cholinergic neurons in brain regions associated with higher cognitive functions, i. e. in the neocortex and hippocampus, as well as from the increase in BChE level is observed, reaching up to 165 % of its normal level [ 5 , 6 ] . Cholinesterase inhibitors (ChEI) constitute an important group of compounds used in the symptomatic treatment of Alzheimer's disease. They support cholinergic transmission by inhibiting acetylcholinesterase cleavage. Most commonly administered agents from this group include donepezil and galantamine, both being acetylcholinesterase inhibitors (AChEI), and rivastigmine, which inhibits both acetylcholinesterase and butyrylcholinesterase (AChEI, BChEI). Studies revealed that the administration of such double inhibitors is particularly favorable at later stages of Alzheimer's disease [ 7 -10 ] . In the study, synthesis and biological evaluation of a series of new donepezil derivatives with hydrazine nicotinate moiety as potential cholinesterase inhibitors are described. Inhibitory activity of acetylcholinesterase and butyrylcholinesterase of the obtained compounds was studied using the method of Ellman, to determine the rate of hydrolysis of acetyltiocholine (ATCh) in the presence the inhibitor [ 11 ] .
Material and Methods
▼
Chemistry
Reaction was monitored by TLC using DC-Alufolien Kieselgel 60F254 plates (Merck), with detection by UV lamp (254 nm). Melting points were measured on an Electrothermal apparatus in open capillaries and are uncorrected. Column chromatography was performed using silica gel 60 (230-400 mesh, Merc). IR spectra were recorded in KBr using a Mattson Infi nity Series FT-IR spectrophotometer.
1 H NMR spectra were recorded with a
Varian Mercury 300 MHz spectrometer, using tetramethylsilane as internal standard. Elemental analyses were recorded using Perkin Elmer series II, CHNSO, Analyzer 2400. Mass spectra were performed by the Centre of Molecular and Macromolecular Studies in Lodz.
6-hydrazinopyridine-3-carboxylic acid (1)
6-chloronicotinic acid (50.8 mmol) was added to 80 % hydrazine hydrate (930.0 mmol) and placed in a 100 °C oil bath for 4 h. The homogenous reaction mixture was cooled to room temperature and concentrated to dryness to give a white solid. The solid was dissolved in water and on acidifi cation to pH 5.5 with concentrated hydrochloric acid, a precipitate was formed. The precipitate was isolated by fi ltration and was washed with ethanol and ether, and dried in vacuum. 6-Boc-hydrazinopyridine-3-carboxylic acid (2)
To a solution 1 (9.8 mmol) and triethyl amine (11.8 mmol) in DMF (10 mL) was added di-tert -butyl dicarbonate (9.8 mmol General procedure for the synthesis of compounds (5) and (6) 5-hydroxyindan-1-one (5.0 mmol), paraformaldehyd (5.0 mmol) and the corresponding amine were dissolved in isopropanol (20 mL). Afterwards, the pH of the suspension was adjusted to 2-3 with concentrated hydrochloric acid. The mixture was refl uxed for 5 h. The solution was them evaporated to the half of the initial volume and crude precipitate was fi ltered off . The dry solid was recrystallized from methanol.
5-hydroxy-2-piperidin-1-ylmethylindan-1-one hydrochloride (5) General procedure for synthesis of compounds (7) and (8)
To solution of 1 M NaOH (20.1 mmol) in tert-butyl alcohol (6 mL) was added the corresponding n-bromoalkylamine hydrobromide (9.1 mmol) and di-tert-butyl dicarbonate (10.1 mmol). The reaction mixture was stirred for 12 h in room temperature, and then was washed with 0.1 M HCl, and 5 % NaHCO 3 , and brine. The organic layer was dried over Na 2 SO 4 and concentrated in vacuo to give N-Boc-3-bromoalkylamine as yellow oil.
N-Boc-2-bromoethylamine (7) Yield 84 %. IR (KBr) cm 
5-Boc-aminopentanol (9)
To a mixture of 5-aminopentanol (10.0 mmol) in acetonitrile (50 mL) was dropwise added di-tert-butyl dicarbonate (10.0 mmol) dissolved in acetonitrile (5 mL 
General procedure for synthesis of compounds (14) and (15) TEA (2.0 mmol) and triphenylphosphine (Ph 3 P) (2.5 mmol) were added to solution 5 , 6 (2.0 mmol) in anhydrous THF (5 mL) under argon. The mixture was stirred and cooled in a ice bath (− 5 °C to 0 °C), while diethylazodicarboxylate (2.5 mmol) was added dropwise. After 15 min, N-Boc-aminopentanol (2.0 mmol) in DMF (1 mL) was added all at once. The reaction mixture was stirred overnight, and warmed to room temperature. The mixture was concentrated under reduced pressure. The crude product in the form of oil was purifi ed by silica gel column chromatography, using as eluent mixtures of solvents: chloroform: methanol: NH 3 saturated 9:1:0.5.
5-(5-Boc-aminopentyloxy)-2-piperidin-1-ylmethylindan-1-one (14)
Yield 48 %. IR (KBr) cm 
General procedure for preparation of compounds (16-21)
A solution of 10-15 (0.5 mmol) in anhydrous THF (5 mL) was cooled to -20 °C and stirred for 30 min. Etherate HCl was added dropwise to the reaction mixture under pH = 1. The precipitate was collected by suction fi ltration, washed with ether and dried in desiccator to give a white solid. 
5-(2-aminoethoxy)-2-piperidin-1-ylmethylindan-1-one hydrochloride (16)
General procedure for preparation of compounds (22-27)
1,1'-carbonyldiimidazole (1.0 mmol) was added to solution 2 in anhydrous THF (10 mL). The mixture was stirred for 4 h in room temperature. Next, the corresponding amine 16-21 (1.0 mmol) and TEA (1.0 mmol) were added. The resulting amber solution was stirred for 20 h. The solvent was evaporated under reduced pressure, water was added, and the resultant mixture was extracted twice with CH 3 Cl. The combined organic extracts were washed with brine and then dried with anhydrous Na 2 SO 4 . The solvent was evaporated under reduce pressure and the residue was purifi ed by crystallization from methanol. 
6-Boc-hydrazino-N-[3-(1-oxo-2-piperidin-1-ylmethylindan-5-yloxy)-propyl]-nicotinamide (24)
General procedure for preparation of compounds (28-33)
0.5 mmol 22-27 was dissolved in anhydous THF (5 mL) and ether saturated HCl was dropwise added. Mixture was stirred in room temperature and a percipitate was formed. The percipitate was isolated and the solid was washed with ether. 
6-hydrazino-N-[2-(1-oxo-2-piperidin-1-ylmethylindan-5-yloxy)-ethyl]-nicotinamide hydrochloride (28)
(2H, d, NH 2 ), 1.3-1.7 (5H, m, 2 · CH 2 , 1 · CH), 1.2-1.3 (6H, m, CCH 2 C). MS (FAB) (m/z): 558 (M + 1
Inhibition Studies on AChE and BChE
▼
The activity of acetylcholinesterase (AChE) and butyrylcholinesterase inhibitors was measured spectrophotometricaly according to the colorimetric method of Ellman (1 961) with some modifi cation. The AChE activity was determined in a mixture containing the assay solution consisting of a phosphate buff er (0.1 M, pH 8.0) with the addition of a solution of 5,5'-dithiobisnitrobenzoic acid (DTNB, 0.05 mL, 0.5 M), AChE (5 U/mL) and the appropriate inhibitor (tested compounds). The fi nal assay volume was 3 mL. Inhibitor curves of the diff erent derivatives were obtained using 7 concentrations of acetyltiocholine iodide as the substrate of the enzymatic reaction lasting 1 min. Enzyme activity was determined by measuring the absorbance at 412 nm after 1 min at 37 °C with Perkin Elmer Lambda 25 UV/VIS Spectrophotometer. Sample without inhibitor was consistently available to provide 100 % of AChE activity. The reaction rates and the percent of inhibition due to the presence of tested compounds were compared. Each reaction was independently repeated at least 3 times. Determination of butyrylcholinesterase (BChE) inhibitory activity was carried out in a similar manner using 5 units/L of BChE instead of AChE in the fi nal volume of 3 mL. The IC 50 , defi ned as the concentration of each compound that reduces the enzymatic activity (AChE or BChE) by 50 % with respect to that without inhibitors, was calculated by non-linear and linear regression. DTNB, enzymes (C2629 and C4290) and acetylthiocholine iodide were purchased from Sigma-Aldrich.
Results and Discussion
▼
Chemistry
In the present investigation compound 2 was synthesized following the method described by Abrams ( • ▶ Fig. 1 ) [ 12 ] . 6-chloronicotinic acid and hydrazine hydrate were refl uxed at 100 °C.
In the next step, hydrazine N-atom was protected by di-tert butyl dicarbonate ((t-BuOCO) 2 O) to give 6-Boc-hydrazinopyridine-3-carboxylic acid 2 . Condensation commercially available 5-hydroxyindan-1-on and secondary amines (piperidine 3 , 4-benzylpiperidine 4 ) with paraformaldehyd gave 5, 6 ( • ▶ Fig. 2 ) [ 13 , 14 ] . In the next step, derivatives of 5-hydroxyindan-1-one 5, 6 coupled with alkyl linker through etheric bond. Based on our study, we determined 2 methods for synthesizing compounds with a variable length of the carbon chain at C-5. N-Boc-aminoethoxy derivatives 10, 11 were used to perform O-alkylation of 5, 6 with N-Boc-2-bromoethylamine 7 using potassium carbonate in refl uxing acetonitrile [ 15 ] . Similar reaction conditions employing N-Boc-3-bromopropylamine 8, led to the desired 12, Fig. 3a ) . Treatment of 5, 6 under Mitsunobu conditions, using 5-aminopentanol with N-atom protected by Boc 9 provided 14, 15 ( • ▶ Fig. 3b ) [ 16 -18 ] . N-atom of n-bromoalkylamine and N-atom of 5-aminopentanol were protected following the methods described previously [ 15 , 19 ] . [ 27 ] . All the tested compounds showed a higher inhibitory activity on AChE than BChE, and showed lower inhibition of AChE compared with donepezil. Compound 33 showed the greatest affi nity for AChE, while compound 28 was found to be the least eff ective against this enzyme. We also assessed the impact of the activity of the constructed derivatives obtained against AChE. After analyzing biological activity of the compounds with the same length of carbon chain, it can be concluded that replacing piperidine with benzylpiperidine substituent in compounds 28 , 30 , and 32 (and obtaining compounds 29 , 31 , and 33 , respectively) was refl ected by a slight increase in activity against AChE. For example, the activity of ethyl derivative of benzylpiperidine 29 increased 9-fold as compared to the ethyl derivative of piperidine 28 . Variation of the alkyl linker length between the 2 groups, indanone and Hynic, for piperidine derivatives 28, 30, 32 revealed the penthylenelinked substance to be more active than their propylene and ethylene linked counterparts. In the case of derivatives of N-benzylpiperidine 29 , 31 , 33 , the infl uence of alkylene-linker length was negligible and compounds 31 and 33 showed nearly equal potency in anti-AChE assay. All the tested compounds showed higher inhibition of BChE than the reference (donepezil). The selectivity toward AChE (IC 50 ratio of BChE/AChE) and BChE (IC 50 ratio of AChE/BChE) of the obtained compounds and reference inhibitor (donepezil) were also determined. All the tested compounds showed a higher selectivity for AChE than for BChE, while the selectivity with respect to AChE was less than in the case of the standard (donepezil), selectivity to BChE was greater than for donepezil. Compound 33 was found to be the most potent with regards to AChE activity and the most selective for AChE among the obtained indanone derivatives. The selectivity of this derivative was nearly 50-fold higher compared to the least selective derivative 28 . Concurrently, compound 28 was characterized by the highest selectivity against BChE.
Drug-modeling studies
Docking studies of donepezil-hydrazinonicotinamide hybrids on the active site of electric eel AChE inhibited by donepezil (PDB: 1EA5) revelated their mode of structural and positional requirements for potential activity. These studies elucidated the interaction between electric eel AChE and inhibitors 29-33 . The AChE-Inhibitor complex was generated using Cache software (Fujitsu). Docking analysis performed with these inhibitors 
Conclusion
▼
In summary, series of indanone derivatives with hydrazine nicotinate moiety were synthesized and their anticholinesterase activities were evaluated. All tested compounds exhibited a higher affi nity to AChE than for BChE. Similarly, their selectivity for AChE was greater than for BChE. When compared to donepezil, all synthesized molecules were less active with regards to inhibiting AChE and slightly more active in inhibiting BChE. All tested derivatives were less selective for AChE and BChE, their selectivity is higher than the reference (donepezil). The results indicate that compound 33 (N-benzylpiperidine derivative) was the most eff ective inhibitor of AChE, additionally, it had the highest selectivity for the enzyme. Compound 30 (piperidine derivative) was most active against BChE, however, compound 28 showed the highest selectivity for BChE.
